Risk factors for lung disease progression in children with cystic fibrosis

The European Respiratory Journal
Marieke van HorckEdward Dompeling

Abstract

To identify potential risk factors for lung disease progression in children with cystic fibrosis (CF), we studied the longitudinal data of all children with CF (aged ≥5 years) registered in the Dutch CF Registry (2009-2014).Lung disease progression was expressed as a decline in lung function (forced expiratory volume in 1 s (FEV1) % pred) and pulmonary exacerbation rate. Potential risk factors at baseline included sex, age, best FEV1 % pred, best forced vital capacity % pred, genotype, body mass index z-score, pancreatic insufficiency, medication use (proton pump inhibitors (PPIs), prophylactic antibiotics and inhaled corticosteroids), CF-related diabetes, allergic bronchopulmonary aspergillosis and colonisation with Pseudomonas aeruginosaThe data of 545 children were analysed. PPI use was associated with both annual decline of FEV1 % pred (p=0.017) and future pulmonary exacerbation rate (p=0.006). Moreover, lower FEV1 % pred at baseline (p=0.007), prophylactic inhaled antibiotic use (p=0.006) and pulmonary exacerbations in the baseline year (p=0.002) were related to pulmonary exacerbations in subsequent years.In a cohort of Dutch children with CF followed for 5 years, we were able to identify several risk factors for future ex...Continue Reading

References

Sep 17, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David A StevensUNKNOWN Participants in the Cystic Fibrosis Foundation Consensus Conference
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Tim W R LeeJames M Littlewood
May 3, 2006·Pediatrics·Roberto Berni CananiUNKNOWN Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGEN
May 19, 2006·The European Respiratory Journal·M ProesmansK de Boeck
Jul 24, 2007·The Journal of Pediatrics·Michael W KonstanUNKNOWN Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Jul 7, 2011·World Journal of Gastrointestinal Pharmacology and Therapeutics·Alexander L Fohl, Randolph E Regal
May 9, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Michael W KonstanWayne J Morgan
Jun 30, 2012·The European Respiratory Journal·Philip H QuanjerUNKNOWN ERS Global Lung Function Initiative
Apr 20, 2013·The European Respiratory Journal·Eitan KeremUNKNOWN ECFS Patient Registry Steering Group
Jan 17, 2014·The Lancet. Respiratory Medicine·Hartmut Grasemann, Felix Ratjen
Jan 23, 2014·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M KupczykUNKNOWN BIOAIR investigators
Feb 18, 2014·BMC Pulmonary Medicine·Emily DimangoXinhua Liu
May 13, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F J ReenF O'Gara
May 27, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Alan R SmythSue Wolfe
Sep 16, 2014·Respirology : Official Journal of the Asian Pacific Society of Respirology·Alex Horsley, Salman Siddiqui
Mar 11, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Donald R VanDevanterMichael W Konstan
Mar 13, 2015·Chest·Jessica E Pittman, Thomas W Ferkol
Jun 11, 2015·Pediatric Pulmonology·Jonathan CogenUNKNOWN EPIC Study Group
Sep 22, 2015·The Journal of Pediatrics·Wayne J MorganUNKNOWN Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis
Oct 21, 2015·PloS One·Marlou P M AdriaanseAnita C E Vreugdenhil
Apr 9, 2016·European Journal of Pediatrics·Stephanie DemeyerKatrien Cosaert
May 4, 2016·Lancet·J Stuart Elborn

❮ Previous
Next ❯

Citations

Oct 6, 2018·The European Respiratory Journal·Hafez Al MomaniChris Ward
May 21, 2019·Pediatric Pulmonology·Adrienne P Savant, Susanna A McColley
Oct 6, 2020·Frontiers in Pharmacology·Lucy Perrem, Felix Ratjen
Jan 9, 2019·Frontiers in Pharmacology·Livia DelpianoVinciane Saint-Criq
Jan 5, 2021·Journal of Pediatric Gastroenterology and Nutrition·Racha T KhalafJ Kirk Harris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

The Journal of Pediatrics
Michael W KonstanScientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
The European Respiratory Journal
Eitan KeremECFS Patient Registry Steering Group
American Journal of Respiratory and Critical Care Medicine
Richard KraemerReto Crameri
© 2022 Meta ULC. All rights reserved